9802 related articles for article (PubMed ID: 16370382)
1. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Morse MA
Curr Opin Mol Ther; 2005 Dec; 7(6):588-97. PubMed ID: 16370382
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
Weber J
Cancer Immunol Immunother; 2009 May; 58(5):823-30. PubMed ID: 19198837
[TBL] [Abstract][Full Text] [Related]
3. Accelerating drug development at Bristol Myers Squibb through innovation.
Viraswami-Appanna K; Buenconsejo J; Baidoo C; Chan I; Li D; Micsinai-Balan M; Tiwari R; Yang L; Sethuraman V
Drug Discov Today; 2024 May; 29(5):103952. PubMed ID: 38508230
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: it takes a village.
Pardoll D
Science; 2014 Apr; 344(6180):149. PubMed ID: 24723594
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor immunity by CTLA-4 blockade.
Leach DR; Krummel MF; Allison JP
Science; 1996 Mar; 271(5256):1734-6. PubMed ID: 8596936
[TBL] [Abstract][Full Text] [Related]
6. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma.
Bajetta E; Rimassa L; Carnaghi C; Del Vecchio M; Celio L; Cassata A
Tumori; 1998; 84(1):48-51. PubMed ID: 9619714
[TBL] [Abstract][Full Text] [Related]
7. Decision in the management of cutaneous malignant melanoma.
Goldman LI
Semin Oncol; 1980 Dec; 7(4):370-5. PubMed ID: 7466406
[TBL] [Abstract][Full Text] [Related]
8. Strategies for validation.
Lew RA
Natl Cancer Inst Monogr; 1985 May; 67():161-8. PubMed ID: 4047145
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.
Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB
Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832
[TBL] [Abstract][Full Text] [Related]
10. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Sherburn TE; Gale JM; Ley RD
DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
[TBL] [Abstract][Full Text] [Related]
11. External ATP-induced passive permeability change and cell lysis of cultured transformed cells: action in serum-containing growth media.
Kitagawa T; Amano F; Akamatsu Y
Biochim Biophys Acta; 1988 Jun; 941(2):257-63. PubMed ID: 3382648
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of human tumors in nude mice.
Shimosato Y; Kameya T; Nagai K; Hirohashi S; Koide T; Hayashi H; Nomura T
J Natl Cancer Inst; 1976 Jun; 56(6):1251-60. PubMed ID: 186624
[TBL] [Abstract][Full Text] [Related]
13. Stage I melanoma of the limbs. Immediate versus delayed node dissection.
Veronesi U; Adamus J; Bandiera DC; Brennhovd IO; Caceres E; Cascinelli N; Claudio F; Ikonopisov RL; Javorskj VV; Kirov S; Kulakowski A; Lacour J; Lejeune F; Mechl Z; Morabito A; Rodé I; Sergeev S; van Slooten E; Szczygiel K; Trapeznikov NN; Wagner RI
Tumori; 1980 Jun; 66(3):373-96. PubMed ID: 7003869
[TBL] [Abstract][Full Text] [Related]
14. [Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues].
Gaiser T; Rüschoff J; Schally AV; Keller G; Engel JB
Verh Dtsch Ges Pathol; 2006; 90():186-92. PubMed ID: 17867596
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of magnesium and calcium on integrin-mediated melanoma cell migration on type IV collagen and fibronectin.
Yoshinaga IG; Dekker SK; Mihm MC; Byers HR
Melanoma Res; 1994 Dec; 4(6):371-8. PubMed ID: 7703716
[TBL] [Abstract][Full Text] [Related]
16. ADCC of cultured human melanoma cells: analysis with monoclonal antibodies to human melanoma-associated antigens.
Imai K; Ng AK; Glassy MC; Ferrone S
Scand J Immunol; 1981 Oct; 14(4):369-77. PubMed ID: 7336169
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic nevi and malignant melanoma.
Metcalf JS; Maize JC
Dermatol Clin; 1985 Apr; 3(2):217-24. PubMed ID: 3830485
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal anti-keratin (AE1) reactivity in routinely processed tissue from 166 human neoplasms.
Spagnolo DV; Michie SA; Crabtree GS; Warnke RA; Rouse RV
Am J Clin Pathol; 1985 Dec; 84(6):697-704. PubMed ID: 2416215
[TBL] [Abstract][Full Text] [Related]
19. Dysplastic vulvar nevi.
Blickstein I; Feldberg E; Dgani R; Ben-Hur H; Czernobilsky B
Obstet Gynecol; 1991 Nov; 78(5 Pt 2):968-70. PubMed ID: 1923241
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous tumor regression: possible relationship to in vitro parameters of tumor immunity.
Hellström KE; Hellström I
Natl Cancer Inst Monogr; 1976 Nov; 44():131-4. PubMed ID: 193017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
